Fig. 4From: Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance SystemKaplanāMeier analysis of overall survival stratified by sequencing, except EVE for patients after age, sex, and CCI matchingBack to article page